Coordination of Benefit

01Conceptual Foundation and Rationale

Indonesia operates a universal social health insurance system through the JKN (Jaminan Kesehatan Nasional) program administered by BPJS Kesehatan. By design, JKN provides baseline coverage for all citizens, but the benefit package is limited to the participant's ward class entitlement, and access to referral hospitals requires a tiered referral from a primary care facility (FKTP).

Many employed Indonesians and their families also carry commercial health insurance (Asuransi Kesehatan Tambahan, or AKT) through their employer or individual purchase. Before KAPJ, these two insurance layers operated independently. A patient with both coverages faced a fragmented experience: they could use JKN with its referral chain and basic ward, or they could use their commercial policy entirely separately. There was no formal mechanism for the two payers to share the cost of a single episode of care.

Coordination of Benefits solves this problem. The concept originates from commercial insurance practice, where a primary insurer pays first and a secondary insurer covers the residual. In Indonesia's adaptation, the BPJS Kesehatan acts as the primary payer (covering the JKN baseline), and the commercial insurer acts as the secondary payer (covering the cost difference when the patient upgrades their ward class or accesses care through an alternative pathway). This cost difference is called the selisih biaya (cost differential).

The term "COB" itself was used in earlier regulations (notably Perpres 19/2016, Pasal 27). However, Perpres 82/2018 replaced the COB nomenclature with "Koordinasi Antar Penyelenggara Jaminan" (KAPJ), reflecting the view that traditional COB belongs to commercial insurance, while Indonesia's system coordinates a social insurance program with commercial supplements. For exam purposes, treat COB and KAPJ as functionally interchangeable terms, but know that the current regulatory language favors KAPJ.

The INA-CBG tariff is central to understanding every calculation in KAPJ. INA-CBG (Indonesian-Case Based Groups) is the bundled payment rate that BPJS Kesehatan pays to referral-level hospitals (FKRTL) for a package of services grouped by diagnosis and procedure, as regulated by PMK 3/2023. This tariff is the denominator in every cost-sharing formula you will see.

02Regulatory Framework

This is a high-yield section. Exam questions often test your ability to identify which regulation governs which aspect of KAPJ.

03The Two Service Pathways (Clinical Application)

This is the most testable section. You need to know both pathways, the cost splits, and which payer bears the burden.

Why the 75%/125% split matters:

Under the KMK 1366/2024 guideline, BPJS Kesehatan covers 75% of the INA-CBG tariff corresponding to the patient's entitled ward class, and the commercial insurer covers the difference between the hospital's actual charges and the BPJS portion. The critical conceptual point is that this is NOT a simple percentage split of the total bill. Instead, BPJS pays its fixed 75% of the INA-CBG benchmark, and AKT absorbs whatever lies between that amount and what the hospital actually charges, subject to the cap.

Example (Pathway 1 with referral):
Suppose the INA-CBG tariff for a given diagnosis/class is Rp50,000,000. The hospital charges Rp80,000,000 for the upgraded ward.

• BPJS covers: 75% x Rp50,000,000 = Rp37,500,000

• Maximum billable to AKT: 125% x Rp50,000,000 = Rp62,500,000

• AKT pays: Rp80,000,000 - Rp37,500,000 = Rp42,500,000 (within the 125% cap)

• Patient pays: Rp0

Example (Pathway 2 without referral):
Same INA-CBG tariff of Rp50,000,000. The hospital charges Rp100,000,000.

• BPJS does not directly reimburse

• Maximum billable amount: 250% x Rp50,000,000 = Rp125,000,000

• Since actual charge (Rp100,000,000) < cap (Rp125,000,000), AKT covers Rp100,000,000

• Patient pays: Rp0

04Co-Payment and Risk Sharing (POJK 36/2025)

This regulation is frequently tested because it was newly introduced and affects all commercial health insurance products in Indonesia.

The initial SEOJK No. 7/2025 had set co-payment at 10%, but after pushback from the national legislature (Komisi XI DPR RI), the POJK 36/2025 lowered it to 5%. This legislative history is a common exam trap: students may recall the 10% figure from the earlier circular letter and incorrectly apply it.

The shift from per-event deductible to annual deductible is conceptually important. Under the old system, the patient faced a deductible reset with every single claim event. Under the new regulation, once the annual deductible threshold is reached, subsequent claims within the same policy year are fully covered by the insurer. This is more favorable for patients with chronic conditions requiring repeated care.

05Eligibility Requirements and Implementation Status

The active membership requirement is a frequently tested detail. A patient whose JKN contributions are in arrears (more than one month overdue) loses active status and cannot access KAPJ, even if they hold a valid commercial policy.

06Institutional Roles

07Differential Concepts and Exam Distractors

08Traps and High-Yield Pearls

Trap 1: Confusing the 200% and 250% caps. The 200% INA-CBG cap applies to Pathway 1 (with referral), where BPJS and AKT share costs. The 250% cap applies to Pathway 2 (without referral), where AKT pays alone. Students who mix up these pathways will incorrectly calculate the maximum billable amount.

Trap 2: Applying the old 10% co-payment figure. SEOJK 7/2025 initially set co-payment at 10%, but POJK 36/2025 lowered this to 5% after legislative review. The current enforceable standard is 5%.

Trap 3: Assuming KAPJ eliminates the referral requirement entirely. KAPJ offers two pathways, but Pathway 2 (without referral) shifts the entire financial burden to the commercial insurer. The JKN system's tiered referral principle remains intact for those who wish to use the BPJS-AKT cost-sharing split.

Trap 4: Forgetting the active membership requirement. The exam may present a vignette where a patient holds both JKN and commercial coverage, but has lapsed JKN contributions. In that scenario, KAPJ does not apply, and the patient cannot access the coordinated benefit. Active JKN status is a hard prerequisite.

Trap 5: Confusing KAPJ with traditional COB. COB is a commercial insurance concept. Indonesia's system coordinates a social insurance program with commercial supplements, which is why the regulatory language shifted to KAPJ. Exam questions may use the terms interchangeably in the stem but test whether you understand the structural difference.

Trap 6: Ignoring the PKS requirement. A patient cannot simply walk into any hospital and expect KAPJ to apply. The hospital must have signed a formal PKS with both BPJS Kesehatan and the patient's commercial insurer. Without this tripartite agreement, KAPJ does not activate.

Core competency being tested: The exam is evaluating whether you understand the architecture of Indonesia's multi-payer health financing system, can correctly identify which payer bears which portion of costs under each pathway, know the regulatory hierarchy governing KAPJ, and can distinguish coordinated payment from fraudulent double claiming or independent cost-sharing arrangements. Vignettes will typically present a patient scenario and ask you to identify the correct payment split, determine eligibility, or select the applicable regulation.